The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
10-Mar-25
Pending
$975 million
Target:
Avail Infrastructure Solutions
Acquiror:
nVent Electric plc
Advised Avail Infrastructure Solutions on the sale of its Electrical Products Group, a leading provider of specialized products and solutions designed to support industrial and electrical applications, to nVent Electric plc (NYSE: NVT), a global leader in electrical connection and protection solutions
13-Feb-25
Pending
$890 million
Target:
Renewi plc
Acquiror:
Consortium controlled by Macquarie Asset Management and BCI
Advising Renewi plc, a leading European waste-to-product company, on its £707 million recommended cash offer for its entire issued share capital from a consortium controlled by Macquarie Asset Management and British Columbia Infrastructure Management Corporation (BCI)
24-Dec-24
Undisclosed
Target:
Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)
Acquiror:
Neuraxpharm Group
Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)
29-Nov-24
Pending
$320 million (AUD value)
Target:
Pacific Smiles Group
Acquiror:
Genesis Capital
Advised Pacific Smiles Group Limited, one of Australia’s leading and fastest growing dental service organisations, on its response to multiple private equity proposals and ultimate sale to Genesis Capital by way of off-market takeover
03-Oct-24
$1.1 billion
Target:
Tyman plc
Acquiror:
Quanex Building Products Corporation
Advised Tyman plc, a leading international supplier of fenestration components and access solutions to the construction industry, on the recommendation of a cash and share acquisition by Quanex, a global NYSE listed manufacturing company serving OEMs in the fenestration, cabinetry, solar, refrigeration and outdoor products markets
25-Sep-24
Pending
$115 million
Target:
Markforged Holding Corporation
Acquiror:
Nano Dimension Ltd.
Advising Nano Dimension, a developer of 3D printing and Additive Manufacturing technologies, predominantly for A&D applications, on its acquisition of Markforged, a developer of digital 3D printing solutions in metal and advanced composites
28-Aug-24
Pending
Undisclosed
Target:
EthosEnergy
Acquiror:
One Equity Partners
Advised One Equity Partners, a middle market private equity firm, on the acquisition of EthosEnergy, a global independent turbine and rotating equipment service provider for power and process industries and for aerospace & defense markets
03-Jul-24
Pending
$310 million
Target:
Desktop Metal, Inc.
Acquiror:
Nano Dimension Ltd.
Advising Nano Dimension, a developer of 3D printing and Additive Manufacturing technologies, predominantly for A&D applications, on its acquisition of Desktop Metal, a vertically integrated 3D printers, materials and software company and pioneer of several 3D printing technologies
09-Apr-24
Undisclosed
Target:
Tegra’s Operating Entities in Honduras, El Salvador, and the U.S.
Acquiror:
SAE-A Trading
Advising Tegra, a premier and leading near and onshore apparel manufacturer for sport, team, and performance apparel, on the sale of its operating entities in Honduras, El Salvador, and the U.S. to SAE-A Trading, a vertically integrated textile and apparel garment manufacturer
20-Feb-24
Pending
$185 million
Target:
myHomecare Group
Acquiror:
Australian Unity
Advising Australian Unity on its acquisition of myHomecare Group
14-Feb-24
Undisclosed
Target:
Huntswood CTC Limited
Acquiror:
The Results Companies, LLC
Advised Huntswood CTC Limited, a business process and outsourcing company, on its sale to The Results Companies, LLC (“ResultsCX”), a global Customer Experience Management company backed by ChrysCapital
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
13-Jul-23
$224 million
Target:
Distribuidora Internacional Carmen SAU
Acquiror:
Diploma PLC
Advised Diploma PLC in the acquisition of Distribuidora Internacional Carmen SAU (“DICSA”), a market-leading distributor of fluid power solutions into the European aftermarket
01-Jun-23
$90.4 million
Target:
PCAS Canada Inc.
Acquiror:
DIC Corporation
Advised DIC Corporation, a Japanese specialty chemical company, on the acquisition of PCAS Canada Inc., a contract manufacturer of high-quality photoresist polymers, from PCAS SA, a French manufacturer of complex molecules for Life Sciences and Specialty Chemicals markets which is a majority-owned subsidiary of SK Capital-backed Seqens
27-Apr-23
$403 million
Target:
Distrelec BV
Acquiror:
RS Group plc
Advised RS Group plc on the acquisiton of Distrelec, a high-service, digital-led distributor of industrial MRO and electronic products
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
05-Apr-23
Pending
$185 million
Target:
Calibre Group’s QuadR Business
Acquiror:
WSP Global Inc.
Advising Calibre Group, an Australian diversified engineering group, on the sale of its Calibre QuadR business to WSP Global Inc., a leading global engineering and professional services firm
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
07-Mar-23
Undisclosed
Target:
David Brown Santasalo
Acquiror:
Stellex Capital Management
Advised N4 Partners on the sale of David Brown Santasalo (DBS), UK based industrial gear manufacturer, to Stellex Capital Management
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
30-Nov-22
Pending
Undisclosed
Target:
Calibre Group’s Built Environment Business
Acquiror:
Egis S.A.
Advised Calibre Group, a leading Australian provider of sustainable engineering solutions, on the sale of its Built Environment business to Egis S.A., a French headquartered global consulting and engineering services firm owned by Tikehau Capital and Caisse des Dépôts
28-Nov-22
Pending
$650 million
Target:
Brambles (CHEP China)
Acquiror:
Loscam Greater China
Adviser to Brambles on the merger of its China business (CHEP China) with Loscam Greater China
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
13-Oct-22
$47 million
Target:
Electro Optic Systems
Acquiror:
Washington H. Soul Pattinson
Advised Electro Optic Systems, an Australian founded and listed aerospace and defence company, on agreeing financing terms with its largest shareholder, Washington H. Soul Pattinson